12 results about "SORBITAN TRIOLEATE" patented technology

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

Pharmaceutical aerosol formulations containing pre-micronized albuterol sulfate, high amount of green propellant trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)), and a surfactant (polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polyethylene glycol 1000, span 85 (sorbitan trioleate), polyvinylpyrrolidone K25, or their combination) in a pressurized metered dose inhaler are described. The formulations do not use any co-solvent, i.e., they are co-solvent-free (e.g., free of ethanol, glycerol, propylene glycol, and a combination thereof). The formulations provide highly efficient delivery, through metered dose inhaler (MDI), of pre-micronized albuterol particles into the patients' respiratory tracts and have the advantages of high efficacy, improved safety, and a low global warming potential (GWP) for environmental impact.

The application belongs to the technical field of biological medicine, and particularly relates to an adjuvant influenza vaccine and a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS buffer solution; the adjuvant is prepared by using mixed oil and an auxiliary agent, the mixed oil comprises squalene, medium-chain triglyceride and alpha-tocopherol; and the auxiliary agent comprises sorbitan trioleate Span-85, Tween 80 and vitamin E succinate polyethylene glycol ester. The adjuvant influenza vaccine prepared by the application has good immunization effect, and can especially improve the overall effect of a tetravalent adjuvant influenza vaccine on four viruses.

The invention belongs to the technical field of biological medicines, and particularly relates to an adjuvant influenza vaccine as well as a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS (Phosphate Buffer Solution), the adjuvant is prepared by using mixed oil and an auxiliary agent, wherein the mixed oil comprises squalene, medium chain triglyceride and alpha-tocopherol; the auxiliary agents comprise sorbitan trioleate Span-85, Tween 80 and vitamin E succinic acid polyethylene glycol ester. The prepared adjuvant influenza vaccine is good in immune effect, and especially the overall effect of the tetravalent adjuvant influenza vaccine on four viruses can be improved.

The invention discloses an anti-wrinkle composition containing a camellia japonica extract and capable of promoting cell energy and an application of the anti-wrinkle composition. The anti-wrinkle composition is prepared from the following components in percentage by mass: 5 to 20 percent of camellia japonica extract, 7.4 to 7.6 percent of flaxseed oil, 0.14 to 0.16 percent of sorbitan trioleate, 0.005 to 0.007 percent of celery seed extract, 0.004 to 0.006 percent of crithmum maritimum extract, 0.003 to 0.004 percent of flaxseed extract and the balance of caprylic / capric triglyceride which is supplemented to 100 percent. The invention further discloses application of the anti-wrinkle composition in promoting synthesis of NAD < + > and ATP in dermal fibroblasts and / or epidermal keratinocytes and / or SIRT3 gene expression and application of the anti-wrinkle composition in preparing cosmetics or skin care products with anti-wrinkle and tightening effects. The composition disclosed by the invention is an oil-soluble composition, is easier to absorb, and can improve the mitochondrial activity through synergistic interaction.

This application relates to the field of lithium batteries, and specifically discloses a lithium battery composite conductive agent, which comprises the following components: conductive particles, organic carriers, binders, colloid materials, dispersants, and solvents; the conductive particles include conductive graphite, carbon fiber, and graphene; the organic carrier is one or two of sorbitan trioleate and lecithin; the colloid material is one or two of guar gum, gelatin, or carrageenan; the dispersant is modified carboxymethyl cellulose. This application also discloses a preparation method of the lithium battery composite conductive agent, which comprises the following steps: S1: Prepare modified carboxymethyl cellulose; S2: Prepare a premixed solution; S3: Prepare a mixed slurry; S4: Prepare a conductive mixed solution; S5: Prepare the lithium battery composite conductive agent. This application has the effect of improving the dispersibility among the components in the composite conductive agent.

The invention discloses preparation and application of a new Newcastle disease bivalent inactivated vaccine containing a composite immunopotentiator, and the vaccine is characterized by comprising the following components: an inactivated Newcastle disease virus antigen solution of which the virus titer is greater than or equal to 10 < 9 > EID50 / mL, an inactivated H9 subtype avian influenza virus antigen solution of which the virus titer is greater than or equal to 10 < 9 > EID50 / mL, and an inactivated H9 subtype avian influenza virus antigen solution of which the virus titer is greater than or equal to 10 < 9 > EID50 / mL. The virus titer is larger than or equal to 10 < 9 > EID50 / mL, the water-phase solution is composed of an inactivated antigen solution and the compound immunopotentiator, and the oil-phase solution is composed of white oil, sorbitan trioleate and aluminum stearate; according to the invention, by adding the composite immunopotentiator, the rapid recognition and reaction of an immune system on antigens can be enhanced, the activation and function of antigen presenting cells can be promoted, and the antigen uptake and treatment capabilities of the antigen presenting cells can be improved, so that the formation of immune response can be accelerated, and the long time of the antigen in vivo can be maintained, thereby prolonging the persistence of the immune response; therefore, the defects of the existing inactivated vaccine in prevention and control of avian influenza and Newcastle disease are overcome.

Pharmaceutical aerosol formulations containing pre-micronized albuterol sulfate, high amount of green propellant trans-1,3,3,3-tetrafluoropropene (HFO-1234ze (E)), and a surfactant (polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polyethylene glycol 1000, span 85 (sorbitan trioleate), polyvinylpyrrolidone K25, or their combination) in a pressurized metered dose inhaler are described. The formulations do not use any co-solvent, i.e., they are co-solvent-free (e.g., free of ethanol, glycerol, propylene glycol, and a combination thereof). The formulations provide highly efficient delivery, through metered dose inhaler (MDI), of pre-micronized albuterol particles into the patients' respiratory tracts and have the advantages of high efficacy, improved safety, and a low global warming potential (GWP) for environmental impact.

The application discloses a squalene-based water-in-oil-in-water vaccine adjuvant and a vaccine composition and application thereof. The adjuvant comprises squalene, tocopherol, lipophilic surfactant and a hydrophilic surfactant combination composed of polyglyceryl dioleate, decaglyceryl monolaurate and polyoxyethylene sorbitan trioleate in a specific mass ratio. The specific combination is the key to forming a stable and uniform squalene multiple emulsion. The vaccine composition prepared by mixing and emulsifying the adjuvant with an antigen shows excellent physical stability, enhanced immune response and good safety in animal experiments, and is especially suitable for preventing bovine nodular dermatosis and preparation of positive serum thereof. The application solves the technical problem that squalene is difficult to stabilize in a complex emulsion system, and provides a replacement scheme superior to a traditional mineral oil adjuvant.

The invention relates to the technical field of vaccine preparations, and discloses an oil-in-water adjuvant containing squalene as well as a preparation method and application of the oil-in-water adjuvant. Polysorbate 80; sorbitan trioleate; a temperature sensitive nonionic block copolymer; an amino acid CMT modulator; a polyol CMT modifier; citric acid; sodium citrate; and the balance of water for injection. The preparation method comprises the following steps: preparing an oil phase; the preparation method comprises the following steps: dissolving a temperature-sensitive nonionic block copolymer, a CMT regulator, citric acid and sodium citrate in low-temperature water for injection, and carrying out heating pretreatment to obtain a water phase; shearing and emulsifying the water phase and the oil phase at a specific temperature; and finally, carrying out speed-controlled cooling and filtering on the hot emulsion. Through the composite formula and the specific process, the long-term storage stability of the adjuvant is remarkably improved, the immunocompetence of the vaccine is guaranteed, the process reproducibility is good, and the production cost is reduced.

The present invention discloses a pesticide spreading agent for green orange trees and a preparation method thereof. The active ingredients of the pesticide spreading agent for green orange trees disclosed by the present invention are polyoxyethylene sorbitan trioleate and sodium dodecylbenzenesulfonate. The spreading agent for green oranges of the present invention can reduce the contact angle between the liquid droplets of the liquid medicine and the green orange leaf surface, change the surface tension, achieve the maximum coverage, effectively improve the adhesion, wetting and spreading ability of the droplets on the green orange leaves, enable the pesticide to be effectively deposited and covered on the green orange tree leaves, reduce the loss of the liquid medicine, reduce the drift of the droplets, improve the utilization rate of the pesticide, and also has the characteristics of low cost and environmental friendliness. It can be used for the spraying operations of various spraying pesticides on green orange trees, including insecticides, fungicides, herbicides, plant growth regulators, foliar fertilizers, etc.

The application relates to the technical field of vaccine preparation, and discloses an oil-in-water squalene-containing adjuvant as well as a preparation method and application thereof. The adjuvant comprises the following components: squalene, polysorbate 80, sorbitan trioleate, a temperature-sensitive nonionic block copolymer, an amino acid CMT regulator, a polyhydric alcohol CMT regulator, citric acid, sodium citrate, and the rest is injection water. The preparation method comprises the following steps: preparing an oil phase; dissolving the temperature-sensitive nonionic block copolymer, the CMT regulator, the citric acid and the sodium citrate in low-temperature injection water, then pre-treating by temperature rising to obtain an aqueous phase; shearing and emulsifying the aqueous phase and the oil phase at a specific temperature; and finally, controlling the cooling speed of the hot emulsion and filtering. Through the composite formula and the specific process, the long-term storage stability of the adjuvant is remarkably improved, the immunocompetence of the vaccine is guaranteed, the process reproducibility is good, and the production cost is reduced.